Cit

Appendicitis: Evolving Tools to Diagnose a Classic Disease

Contributing Editor Appendicitis is a common, potentially lethal condition that affects 7% of individuals sometime in their lives. The condition occurs when the appendix, a blind pouch of intestine at the proximal colon, becomes obstructed by mucus, stool, or lymphatic tissue. Infection ensues, which can rapidly evol...

Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy

Positive interim results prompt request for meeting with FDA SEATTLE, July 11, 2007 /PRNewswire-FirstCall/ -- CellTherapeutics, Inc. (CTI) announced today that interim results ofits phase II/III trial comparing CPOP-R, in which pixantrone issubstituted for doxorubicin in standard CHOP-R first-line treatmentof patients with aggressive non-Hodgkin's lymphoma (NHL), resultedin essentially al...

Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine

- Phase II Results Published in the Journal of Clinical Oncology - NEW YORK, July 06, 2007 /PRNewswire-FirstCall/ -- Results from aPhase II study - which will be published in the August 10, 2007issue of the Journal of Clinical Oncology (JCO) and are nowavailable as an Early Release Article at <a target="_blank" href="http://www.jco.org/">www.jco.org - demonstrate thatixabepilone, a Br...

Avexa's Apricitabine Clinical Trial Update

MELBOURNE, Australia--(BUSINESS WIRE)--Jul 5, 2007 - Australianbiotechnology company Avexa (ASX:AVX) announced today thecompletion of apricitabine's controlled, double blinded phase whichrepresents the first 24 week segment of its Phase IIb trial.Patients have now progressed into the open-label section of thetrial (weeks 24 to 48) and will continue to receive 800mgapricitabine twice a day a...

RTA 402 Shown to Protect Animals Against Toxicities of Standard Cancer Treatments

IRVING, Texas--(BUSINESS WIRE)--Jun 29, 2007 - ReataPharmaceuticals, Inc. today announced the presentation of newpreclinical data showing their lead anti-cancer agent, theSynthetic Triterpenoid RTA 402, is effective at protecting againstcommon toxicities caused by traditional cancer treatments. Thisdata was presented at the annual meeting of the MultinationalAssociation of Supportive Care i...

Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone

Interim results in a randomized phase II/III clinical trialanticipated later this year SEATTLE, June 26, 2007 /PRNewswire-FirstCall/ -- CellTherapeutics, Inc. (CTI) announced the publication of preclinicalstudies, which demonstrate that treatment with pixantrone (BBR2778) resulted in minimal or no significant cardiotoxicity, whiledoxorubicin and mitoxantrone induced significant cardiac da...

Valopicitabine Combined with Standard of Care Cleared Hepatitis C Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a Phase II Trial

~ Valopicitabine achieved both primary and secondary endpoints ofstudy; no negative drug-drug interaction was observed betweenvalopicitabine and ribavirin ~ CAMBRIDGE, Mass., June 12, 2007 /PRNewswire-FirstCall/ -- IdenixPharmaceuticals, Inc. today announced results from a phase II studydesigned to evaluate triple combination therapy, consisting ofvalopicitabine (NM283), Idenix's lead dru...

XYOTAX More Cost Effective With Fewer Side Effects Than Gemcitabine or Vinorelbine in Treating Non-Small Cell Lung Cancer

ASCO publication highlights health care cost benefit ofbioengineering paclitaxel CHICAGO, June 05, 2007 /PRNewswire-FirstCall/ -- CellTherapeutics, Inc. (CTI) announced that data published in the 2007Annual Meeting of the American Society of Clinical Oncology (ASCO)abstracts showed reduced medical resource utilization (MRU) andassociated costs with XYOTAX (paclitaxel polyglumex) treatment...

Vision Deficit in Retinitis Pigmentosa Mice Corrected with DNA Nanoparticles

CLEVELAND--(BUSINESS WIRE)--Jun 4, 2007 - Copernicus Therapeutics,Inc. announced today that a research team at University of OklahomaHealth Sciences Center, led by Dr. Muna Naash, Professor of CellBiology, demonstrated that Copernicus' DNA nanoparticles correctedvision defects in a mouse model of retinitis pigmentosa (RP). Thesefindings were presented at the American Society of Gene Therapy...

Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term Protection and Sterilizing Immunity in Nonhuman Primates

SEATTLE, May 31, 2007 /PRNewswire-FirstCall/ -- VicalIncorporated today announced that a measles DNA vaccine formulatedwith the company's Vaxfectin(TM) adjuvant elicited protectivelevels of neutralizing antibodies in juvenile (1 - 2 year old)nonhuman primates confirmed by complete protection followingchallenge more than one year after vaccination, and sterilizingimmunity as evidenced by...

Cyclacel Pharmaceuticals to Report Sapacitabine Phase I Study Results at the American Society of Clinical Oncology Annual Meeting

BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--May 24, 2007 - CyclacelPharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) announced todaythat it will report results from a Phase I pharmacologic trial ofsapacitabine (CYC682), a novel orally-available nucleoside analog,in patients with advanced leukemias or myelodysplastic syndromes(MDS), at the American Society of Clinical Oncology's (ASCO) Annual...

GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines

Investigational vaccine could offer protectionfor infants against type b andmeningococcal disease — GlaxoSmithKline (GSK) announced results from aPhase II vaccine clinical study presented this week at thePediatri...

Study Supports Cost-Effectiveness of Medtronic's Spasticity Treatment for Children with Cerebral Palsy

MINNEAPOLIS--(BUSINESS WIRE)--Apr 26, 2007 - A new study publishedin the current issue of the Journal of Child Neurology indicatesthat a treatment from Medtronic, Inc. (NYSE:MDT), for spasticity inchildren with cerebral palsy improves their quality of life and iscost-effective compared to other established cost-effectivetreatments. The findings of this Medtronic-sponsored study shouldexpand...

Oncolytics Biotech Inc. Research Collaborators Demonstrate Reovirus/Gemcitabine Combination Has Synergistic Effect Against Human Colon Cancer Cell Lines

CALGARY, April 17, 2007 /PRNewswire-FirstCall/ - OncolyticsBiotech Inc. ("Oncolytics") announces that a poster by Dr. MaureenE. Lane et al. of , New York, entitled "In Vivo Synergy betweenOncolytic Reovirus and Gemcitabine in Ras-Mutated Human HCT116Xenografts" is scheduled to be presented today at the AmericanAssociation for Cancer Research (AACR) Annual Meeting in LosAngeles, CA. The m...

Idenix Reports Results from Two Phase IIb Studies of the Combination of Valopicitabine and Pegylated Interferon in Hepatitis C Genotype-1 Patients at the 42nd Annual Meeting of the European Association for the Study of the Liver

Additional Preclinical Data Presented on Valopicitabine Combinedwith an Investigational Protease Inhibitor BARCELONA, Spain, April 12, 2007 /PRNewswire-FirstCall/ --Idenix Pharmaceuticals, Inc. today announced results from two phaseIIb studies of the novel combination of valopicitabine (NM283) andpegylated interferon alfa-2a (Pegasys(R)) in both treatment-naiveand treatment- experienced p...

Cyclacel Pharmaceuticals to Present Preclinical Data on Sapacitabine and Seliciclib at AACR

BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Apr 11, 2007 - CyclacelPharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) announcedtoday that scientists from the company will present results of twopreclinical studies with sapacitabine and seliciclib, the company'smost advanced drug candidates in clinical development. The resultswill be reported in two poster presentations during the upcomingAnnu...

Mymetics' HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model

Mymetics Also Announces Deal for Vaccine Delivery System NYON, Switzerland, March 29, 2007 /PRNewswire-FirstCall/ --Mymetics Corporation announced today that the Company's HIV vaccineelicited IgA mucosal antibodies in a non-human primate model.Mucosal IgA antibodies are considered a possible first line ofdefense against infection by HIV. The data were presented bySylvain Fleury, Ph.D., My...

Intercell AG: Novel tuberculosis Vaccine Shows Promising Immunogenicity and Safety Profile

The Danish Statens Serum Institut (SSI) and Intercell from a phase I clinicaltrial with a tuberculosis (TB) subunit vaccine The vaccine is produced by SSI and contains Intercell’sadjuvant IC31™...

Oncolytics Biotech Inc. Collaborators to Present Reovirus/Gemcitabine Combination Research at AACR Annual Meeting

CALGARY, March 13, 2007 /PRNewswire-FirstCall/ - OncolyticsBiotech Inc. announced today that an abstract covering preclinicalwork using reovirus in combination with gemcitabine is availabletoday on the American Association for Cancer Research (AACR)website at <a target="_blank" href="http://www.aacr.org/">www.aacr.org , and on the Oncolyticswebsite at <a target="_blank" href="http://...